After issuing a week-long pause on a federal appeals court decision to stop mail orders of the abortion medication mifepristone, the Supreme Court is expected to take further steps in the case by the end of the day Monday. How the court moves forward could have a major impact on the regulatory authority of the Food and Drug Administration as well as on abortion providers and patients.
“The fundamental question is: Who gets to regulate mifepristone?” said Laurie Sobel, an associate director for women’s health policy at KFF. “Can a state go further than the FDA? Is the FDA the floor or the ceiling?”
